DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Malignant Pleural Effusion - Pipeline Review, H1 2017" report to their offering.
Malignant Pleural Effusion - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 3 respectively.
Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Malignant Pleural Effusion - Overview
- Malignant Pleural Effusion - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Malignant Pleural Effusion - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Malignant Pleural Effusion - Companies Involved in Therapeutics Development
- Advantagene Inc
- Biogen Inc
- Genelux Corp
- Shenzen SiBiono GeneTech Co Ltd
For more information about this report visit http://www.researchandmarkets.com/research/tvfq67/malignant_pleural